This effect is not limited just to BRCA related cancers and it is now clear that all HR defective tumours, identified using a RAD51 immunoflourescence assay, are associated with improved survival compared to HR competent tumours when managed with platinum based chemotherapy [1]. The gene discussed is RAD51; the disease is neoplasm.